Whitepaper

Whitepaper: Are nitrosamines a concern for biologic manufacturers?

Nitrosamine genotoxins in several pharmaceuticals has led to monitoring of manufacturing practices for products considered at risk.

The discovery of nitrosamine genotoxins in several pharmaceuticals has led to monitoring and re-evaluation of manufacturing practices for those products considered at risk.

This piece provides an assessment of nitrosamine contamination specifically in biologics and contrasts the potential risks between these product types.